HB-1 / Honeybrains Biotech - LARVOL DELTA

Efficacy and Safety of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Honeybrains Biotech LLC | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Psychiatry

Efficacy and Safety of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Honeybrains Biotech LLC | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Mood Disorders • Psychiatry

Efficacy and Safety of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: Honeybrains Biotech LLC

New P2 trial • CNS Disorders • Mood Disorders • Psychiatry

Safety and Efficacy of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=86 | Completed | Sponsor: Honeybrains Biotech LLC | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Dec 2022

Trial completion • Trial completion date • CNS Disorders • Mood Disorders

Safety and Efficacy of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=86 | Active, not recruiting | Sponsor: Honeybrains Biotech LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2023 ➔ Dec 2023 | Trial primary completion date: May 2022 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders

Safety and Efficacy of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Honeybrains Biotech LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2022 ➔ Jan 2023 | Initiation date: Oct 2021 ➔ Feb 2022 | Trial primary completion date: Oct 2022 ➔ May 2022

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Mood Disorders